Damora Therapeutics, Inc. DMRA
23.22 USD -1.08 (-4.44%)
Regular-session close
23.22 0.00 0.00%
After hours · Nov 20, 4:01 PM ET
23.13 Day range 24.51
16.31 52-week range 34.14
- YTD
- +0.91%
- 1 year
- +33.83%
News
seekingalpha.com Damora Therapeutics, Inc. (DMRA) Presents at UBS Global Biopharma Conference 2026 Transcript Damora Therapeutics, Inc. (DMRA) Presents at UBS Global Biopharma Conference 2026 Transcript
defenseworld.net Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Breaks Above 50 Day Moving Average After Analyst Downgrade Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report)'s stock price passed above its fifty day moving average during trading on Monday after Wall Street Zen upgraded the stock from…benzinga.com Guggenheim Maintains Buy on Damora Therapeutics, Lowers Price Target to $59 Guggenheim analyst Michael Schmidt maintains Damora Therapeutics (NASDAQ:DMRA) with a Buy and lowers the price target from $60 to $59.
benzinga.com Damora Therapeutics Q3 EPS $(0.40) Beats $(0.48) Estimate Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 83.05 percent increase over losses of…
benzinga.com Damora Therapeutics’ Preclinical Data Highlighting Potential Of DMR-001 Accepted For Poster Presentation At 2026 ASH Annual Meeting And Exposition -- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,new data to highlight strong activity against additional non-Type 1 mutations ---- Trial-in-progress…
